Clinical Trial

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, single- and multiple-dose escalating study with a food-effect component, designed to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of YD0293 tablets following a single oral dose in healthy subjects, as well as the effect of food on PK parameters and the potential effect on the QT interval. The study also aims to assess the safety, tolerability, and PK profile of YD0293 tablets following multiple oral doses in healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-24.
Trial Details
NCT Number NCT07098091
Lead Sponsor Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Conditions Healthy Participants
Enrollment 78 participants
Start Date 2025-02-26
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-17